Response to the Comment by Van den Reek et al. on Drug Survival Analysis is not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis
- PMID: 28504087
- DOI: 10.1016/j.ad.2017.03.011
Response to the Comment by Van den Reek et al. on Drug Survival Analysis is not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis
Comment on
-
'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network.Br J Dermatol. 2014 Nov;171(5):1189-96. doi: 10.1111/bjd.13087. Epub 2014 Oct 3. Br J Dermatol. 2014. PMID: 24807471
-
Comment on "Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis".Actas Dermosifiliogr. 2017 Sep;108(7):695-696. doi: 10.1016/j.ad.2017.03.012. Epub 2017 May 11. Actas Dermosifiliogr. 2017. PMID: 28504083 English, Spanish. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
